TEVA

Teva Pharmaceutical Industries Limited · NYSE · Healthcare · USD · 10-K for 2025, filed 2026-02-03

Figures on this page computed 2026-11-08 12:41 UTC

Last close

41.85USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-02-03

34.6xP/E
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-03
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
- 10-Q for 2025, filed 2026-11-03
- 10-K for 2025, filed 2026-02-03
- 10-Q for 2025, filed 2026-11-03
The filing itself
8.2%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
The filing itself
6.7%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-K for 2025, filed 2026-02-03
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
- 10-K for 2025, filed 2026-02-03
- 10-Q for 2025, filed 2026-11-03
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Safety is the furthest below its sector's middle: 0.29 against 0.53 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Against its rival

lens 4 of 9

Measure by measure

behind on 2 of 4

Profit on each unit of sales8.2%2.4%Ahead
Higher is better here.
Return on the capital it usesn/a1.8%n/a
Higher is better here.
Sales growth over five years0.7%6.8%Behind
Higher is better here.
Debt against equityn/a0.73n/a
Lower is better here.
Gross margin51.8%65.5%Behind
Higher is better here.
Price against earnings34.6x96.6xAhead
Lower is better here.

The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.

Against Takeda Pharmaceutical Company Limited, TEVA is behind on 2 of 4 measures.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-03

Profit on each unit of sales8.2%
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
The filing itself
Return on the capital it usesn/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
The filing itself
Sales growth over five years0.7%
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
The filing itself
Debt against equityn/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
The filing itself
Gross margin51.8%
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
The filing itself
Price against earnings34.6x
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-034532
Reported in
USD
The filing itself